Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC

Clinical trial NCT07235306 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07235306
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC Stage III Ensartinib Chemoradiotherapy ALK

Start date: 2025-12-01
Primary completion: 2031-01-31
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.